Promising new combo therapy targets Hard-to-Treat lymphoma
NCT ID NCT02180711
First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times
Summary
This study is testing a drug called acalabrutinib, alone or together with other drugs (rituximab and lenalidomide), in people with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The goal is to see how safe these combinations are and whether they can shrink tumors. About 113 adults are taking part in this early-phase trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- acalabrutinib (a targeted cancer drug) alone or combined with rituximab and lenalidomide
- What this could lead to
- If successful, this could provide a new treatment option for people with certain types of non-Hodgkin lymphoma that have not responded to prior therapy.
- What could go wrong
- This is an early-phase trial with a small number of participants, so results may not apply broadly. Side effects from the drug combinations are possible and being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Tucson, Arizona, 85719, United States
-
Research Site
Downey, California, 90241, United States
-
Research Site
Duarte, California, 91010, United States
-
Research Site
Fountain Valley, California, 92708, United States
-
Research Site
Santa Monica, California, 90404, United States
-
Research Site
Coral Gables FL, Florida, 33146, United States
-
Research Site
Chicago, Illinois, 60611, United States
-
Research Site
Chicago, Illinois, 60612, United States
-
Research Site
Chicago, Illinois, 60637, United States
-
Research Site
Louisville, Kentucky, 40207, United States
-
Research Site
New Orleans, Louisiana, 70112, United States
-
Research Site
Ann Arbor, Michigan, 48109, United States
-
Research Site
Morristown, New Jersey, 07960, United States
-
Research Site
Lake Success, New York, 11042, United States
-
Research Site
New York, New York, 10021, United States
-
Research Site
Columbus, Ohio, 43210, United States
-
Research Site
Greenville, South Carolina, 29615, United States
-
Research Site
Dallas, Texas, 75235, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
San Antonio, Texas, 78217, United States
-
Research Site
Temple, Texas, 76508, United States
-
Research Site
Salt Lake City, Utah, 84112, United States
-
Research Site
Spokane, Washington, 99208, United States
-
Research Site
Edmonton, Alberta, t6G1Z2, Canada
-
Research Site
London, Ontario, N6A 5W9, Canada
-
Research Site
Toronto, Ontario, M5G 2M9, Canada
-
Research Site
Bologna, 40138, Italy
-
Research Site
Milan, 20132, Italy
-
Research Site
Palermo, 90146, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can donor immune cells be engineered to fight blood cancer?